Difference between revisions of "Valacyclovir"
(Tag: 2017 source edit) |
|||
| Line 1: | Line 1: | ||
| + | <languages /> | ||
| + | <translate> | ||
Valacyclovir (VAL-uh-SY-kloh-veer) is a substance that is being studied in the prevention of fungal, bacterial, and viral infections in patients undergoing donor stem cell transplantation with cells that are infected with cytomegalovirus. It belongs to the family of drugs called antivirals. | Valacyclovir (VAL-uh-SY-kloh-veer) is a substance that is being studied in the prevention of fungal, bacterial, and viral infections in patients undergoing donor stem cell transplantation with cells that are infected with cytomegalovirus. It belongs to the family of drugs called antivirals. | ||
| Line 15: | Line 17: | ||
{{antiviral drugs}} | {{antiviral drugs}} | ||
{{coststubd}} | {{coststubd}} | ||
| + | </translate> | ||
Revision as of 23:03, 15 July 2019
Valacyclovir (VAL-uh-SY-kloh-veer) is a substance that is being studied in the prevention of fungal, bacterial, and viral infections in patients undergoing donor stem cell transplantation with cells that are infected with cytomegalovirus. It belongs to the family of drugs called antivirals.
Information about Valacyclovir
Valacyclovir is a nucleoside analogue antiviral agent and prodrug of acyclovir which is used in therapy of herpes and varicella-zoster virus infections. Valacyclovir has been associated with rare instances mild, clinically apparent liver injury.
Mechanism of action of Valacyclovir
Valacyclovir (val" ay sye' kloe vir), which is sometimes spelled valaciclovir, is an acyclic purine nucleoside analogue that is rapidly converted to acyclovir once absorbed. Valacyclovir has greater oral bioavailability than acyclovir and has similar activity against herpes viruses, including herpes simplex 1 and 2, cytomegalovirus, Ebstein-Barr virus and varicella-zoster. Once converted to acyclovir, the drug is phosphorylated intracellularly by viral kinases. The resultant triphosphate competes with guanosine for incorporation into viral DNA, blocking viral DNA polymerase activity. Because its activation requires the presence of viral kinases, valacyclovir is only activated in virally infected cells. Valacyclovir is indicated for therapy of mucocutaneous and genital herpes simplex infections, both type 1 and 2 and for herpes zoster.
FDA approval information for Valacyclovir
Valacyclovir was approved for use in the United States in 1995 and is widely used in the treatment and prophylaxis of genital and mucocutaneous herpes simplex infection. Valacyclovir is available as capsules of 500 mg and 1000 mg generically and under the brand name of Valtrex.
Dosage and administration for Valacyclovir
The usually recommended dose in adults is 500 to 1000 mg once or twice daily. Side effects are uncommon, but include headache, dizziness and gastrointestinal upset.
Drugs for HIV Infection, in the Subclass Antiretroviral Agents
- Fusion Inhibitors (HIV)
- Integrase Inhibitors (HIV)
- Nonnucleoside Reverse Transcriptase Inhibitors (HIV)
- Nucleoside Analogues (HIV)
- Protease Inhibitors (HIV)
HCV NS5A Inhibitors
HCV NS5B Inhibitors (Polymerase inhibitors)
- Asunaprevir, Boceprevir, Glecaprevir, Grazoprevir, Paritaprevir, Simeprevir, Telaprevir, Voxilaprevir
Combination Therapies
Drugs for Herpes Virus
- infections (HSV), CMV, others
Acyclovir, Cidofovir, Famciclovir, Foscarnet, Ganciclovir, Valacyclovir, Valganciclovir
Drugs for Influenza
The article on Valacyclovir is a stub. YOU can help Wikimd by expanding it!
Medication resources
Learn more
About WikiMD
About us: WikiMD is a free medical encyclopedia and wellnesspedia moderated by medical professionals.
Our mission: Provide up to date physician reviewed health, nutrition and wellness information for free in over 100 languages.
Join us: This article is a stub. Help improve Valacyclovir or others. Do not trust amateurs with your life! Join us in this effort!. Paid editors welcome.
